Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1076

1.

The FDA's Experience with Emerging Genomics Technologies-Past, Present, and Future.

Xu J, Thakkar S, Gong B, Tong W.

AAPS J. 2016 Jul;18(4):814-8. doi: 10.1208/s12248-016-9917-y.

2.

An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs.

Kothare PA, Bateman KP, Dockendorf M, Stone J, Xu Y, Woolf E, Shipley LA.

AAPS J. 2016 Mar;18(2):519-27. doi: 10.1208/s12248-015-9860-3.

3.

A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity.

Nieskens TT, Peters JG, Schreurs MJ, Smits N, Woestenenk R, Jansen K, van der Made TK, Röring M, Hilgendorf C, Wilmer MJ, Masereeuw R.

AAPS J. 2016 Mar;18(2):465-75. doi: 10.1208/s12248-016-9871-8.

4.
5.

Gender-Dependent Pharmacokinetics of Veratramine in Rats: In Vivo and In Vitro Evidence.

Lyu C, Zhang Y, Zhou W, Zhang S, Kou F, Wei H, Zhang N, Zuo Z.

AAPS J. 2016 Mar;18(2):432-44. doi: 10.1208/s12248-016-9870-9.

6.

Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.

Kathman S Jr, Thway TM, Zhou L, Lee S, Yu S, Ma M, Chirmule N, Jawa V.

AAPS J. 2016 Mar;18(2):424-31. doi: 10.1208/s12248-015-9853-2.

7.

Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions.

Knopp MM, Nguyen JH, Mu H, Langguth P, Rades T, Holm R.

AAPS J. 2016 Mar;18(2):416-23. doi: 10.1208/s12248-016-9865-6.

8.
9.
10.

Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.

Wang YM, Wang J, Hon YY, Zhou L, Fang L, Ahn HY.

AAPS J. 2016 Mar;18(2):395-403. doi: 10.1208/s12248-015-9857-y. Review.

11.

Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.

Zhang H, Meng J, Zhou S, Liu Y, Qu D, Wang L, Li X, Wang N, Luo X, Ma X.

AAPS J. 2016 Mar;18(2):385-94. doi: 10.1208/s12248-015-9854-1.

12.

Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?

Mayer AP, Hottenstein CS.

AAPS J. 2016 Mar;18(2):287-9. doi: 10.1208/s12248-015-9855-0. Review. No abstract available.

13.

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.

Margolskee A, Darwich AS, Galetin A, Rostami-Hodjegan A, Aarons L.

AAPS J. 2016 Mar;18(2):321-32. doi: 10.1208/s12248-015-9849-y.

14.

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Wang W, Zhou QT, Sun SP, Denman JA, Gengenbach TR, Barraud N, Rice SA, Li J, Yang M, Chan HK.

AAPS J. 2016 Mar;18(2):372-84. doi: 10.1208/s12248-015-9848-z.

15.
16.

Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice.

Piccand M, Bessa J, Schick E, Senn C, Bourquin C, Richter WF.

AAPS J. 2016 Mar;18(2):354-61. doi: 10.1208/s12248-015-9850-5.

17.

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.

Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S.

AAPS J. 2016 Jan;18(1):270-80. doi: 10.1208/s12248-015-9846-1.

18.

R4 Regulator of G Protein Signaling (RGS) Proteins in Inflammation and Immunity.

Xie Z, Chan EC, Druey KM.

AAPS J. 2016 Mar;18(2):294-304. doi: 10.1208/s12248-015-9847-0. Review.

19.

Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines.

Bobbala S, Tamboli V, McDowell A, Mitra AK, Hook S.

AAPS J. 2016 Jan;18(1):261-9. doi: 10.1208/s12248-015-9843-4.

20.
Items per page

Supplemental Content

Loading ...
Support Center